IrelandIreland

University of Cambridge and Elan Pharmaceutical team up against AD

29.11.2011

Dublin/Cmbridge (UK) – The University of Cambridge and Irish drugmaker Elan Pharmaceutical have joined forces in the battle against Alzheimer’s Disease. Together, the two will create a new research centre dedicated to investigating degenerative brain disorders. Elan will be investing US-$10 million in the initial five years of the collaboration, with an option to extend it by a further five years. The goal of the Cambridge-Elan Centre for Research Innovation and Drug Discovery is to discover novel compounds capable of altering the behaviour of proteins associated with neurodegenerative disorders. „Based on this understanding, in conjunction with scientists at Elan, these compounds will be translated into new treatments to prevent these diseases“, said Christopher Dobson, the John Humphrey Plummer Professor of Chemical and Structural Biology at the University of Cambridge and St. John’s College. The research will focus on the protein beta amyloid, which in the brain of Alzheimer patients aggregates and ultimately forms amyloid plaques. „Protein folding, misfolding and turnover are central to neurological disease and will be the basis for further scientific and therapeutic advancement“, commented Ted Yednock, PhD, executive vice president and head of discovery and translation for Elan. His colleague, Dale Schenk, executive vice president and chief scientific officer added that the deal would be in line with Elan’s portfolio of programs in neuroscience and supports the process of discovery which would result in a new line of therapeutics.

IrelandIreland

26.05.2011

Dublin – Ireland’s Elan Corporation plc has paid US$50m to access Proteostasis Therapeutics’ pipeline of proteostasis regulators, peptidomimetic compounds that regulate protein folding, protein aggregation and protein degradation...

IrelandIreland

06.02.2011

Dublin – Irish drug maker Elan Corp. plc announced it has reduced its headcount by 130 (10%) to about 1,200. Elan said a nearly half of the 130 cuts came from the firm’s R&D department, and primarily occurred at its site in San...

IrelandIreland

07.09.2010

Nottingham/Dublin – Irish researchers have identified a new target in S.aureus bacteria that cause progressive bone destruction. According to Tania Claro from Royal College of Surgeons, S. aureus makes use of its surface protein...

IrelandIreland

11.08.2010

Elan Corporation plans to advance ELND005 into phase III testing, despite data indicating that it missed the co-primary endpoints in a phase II AD201 trial for Alzheimer's. According to the trial results, ELND005, a small...

IrelandIreland

03.08.2010

Dublin/St. Paul – Irish researchers have reported that a specific gene variant may increase the severity of multiple sclerosis (MS) symptoms. For the study, which was published in Neurology (3rd August), the research team led by...

IrelandIreland

20.04.2010

Dublin – Irish neuroscience specialist Elan Corporation plc has announced it is investigating the option of spinning out its Elan Drug Technologies business, creating two publicly listed enterprises. Elan is currently assessing...

IrelandIreland

02.03.2010

Dublin – The Elan Corporation has established a novel biomarker, 11C-PiB PET, that can detect whether Alzheimer drug candidates can reduce pathogenic beta-amyloid plaques in the brains of patients. With the new marker, Elan...

IrelandIreland

17.12.2009

Dublin – Irish company Elan Corporation plc and its partner Transition Therapeutics have withdrawn patients from two ongoing phase II trials with the compound ELDN005 following the death of nine patients. The studies were stopped...

Displaying results 11 to 20 out of 49

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-ireland/browse/1/article/university-of-cambridge-and-elan-pharmaceutical-team-up-against-ad.html

Product of the week

Products

Events

All Events

Current issue

All issues